Literature DB >> 31870618

Leukemia inhibitory factor: Recent advances and implications in biotechnology.

Vanessa Pinho1, Mário Fernandes1, André da Costa2, Raúl Machado2, Andreia C Gomes3.   

Abstract

Leukemia inhibitory factor (LIF) is a pleiotropic cytokine with several functions in health and disease ranging from inflammation to cancer. LIF is also a potential target and/or therapeutic agent for diseases such as multiple sclerosis, stroke and even psychological disorders, where the function of LIF as a neurotrophic factor has only recently been explored. In recent years, a limited number of LIF clinical trials have been completed, which partially explains the shortage of effective applications as a therapeutic agent. With the increasing interest from biotechnology companies producing recombinant LIF, this status quo will certainly change, and the potential impact of LIF in terms of disease diagnosis, treatment and management will be realized.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Astrocytes; Brain injury; Cytokine; LIF; Multiple sclerosis; Myelination; Stroke

Mesh:

Substances:

Year:  2019        PMID: 31870618     DOI: 10.1016/j.cytogfr.2019.11.005

Source DB:  PubMed          Journal:  Cytokine Growth Factor Rev        ISSN: 1359-6101            Impact factor:   7.638


  4 in total

1.  Next-Generation Sequencing Analysis of Gastric Cancer Identifies the Leukemia Inhibitory Factor Receptor as a Driving Factor in Gastric Cancer Progression and as a Predictor of Poor Prognosis.

Authors:  Cristina Di Giorgio; Silvia Marchianò; Elisabetta Marino; Michele Biagioli; Rosalinda Roselli; Martina Bordoni; Rachele Bellini; Ginevra Urbani; Angela Zampella; Eleonora Distrutti; Annibale Donini; Luigina Graziosi; Stefano Fiorucci
Journal:  Front Oncol       Date:  2022-06-30       Impact factor: 5.738

Review 2.  Leukaemia inhibitory factor in gastric cancer: friend or foe?

Authors:  Lornella Seeneevassen; Océane C B Martin; Philippe Lehours; Pierre Dubus; Christine Varon
Journal:  Gastric Cancer       Date:  2022-02-02       Impact factor: 7.370

3.  The metabesity factor HMG20A potentiates astrocyte survival and reactive astrogliosis preserving neuronal integrity.

Authors:  Petra I Lorenzo; Eugenia Martin Vazquez; Livia López-Noriega; Esther Fuente-Martín; José M Mellado-Gil; Jaime M Franco; Nadia Cobo-Vuilleumier; José A Guerrero Martínez; Silvana Y Romero-Zerbo; Jesús A Perez-Cabello; Sabrina Rivero Canalejo; Antonio Campos-Caro; Christian Claude Lachaud; Alejandra Crespo Barreda; Manuel Aguilar-Diosdado; Eduardo García Fuentes; Alejandro Martin-Montalvo; Manuel Álvarez Dolado; Franz Martin; Gemma Rojo-Martinez; David Pozo; Francisco J Bérmudez-Silva; Valentine Comaills; José C Reyes; Benoit R Gauthier
Journal:  Theranostics       Date:  2021-05-12       Impact factor: 11.556

Review 4.  Melanoma Progression under Obesity: Focus on Adipokines.

Authors:  Joanna Olszańska; Katarzyna Pietraszek-Gremplewicz; Dorota Nowak
Journal:  Cancers (Basel)       Date:  2021-05-10       Impact factor: 6.639

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.